Adore Settles With Nationwide Class Over Apple Stem Cell Anti-Aging Claims
This article was originally published in The Rose Sheet
Executive Summary
The estimated $700,000 settlement puts to rest allegations that the luxury skin-care firm deceived consumers with claims about its PhytoCellTec ingredient’s ability to slow the aging process. G.M. Collin, another PhytoCellTec Malus Domestica user, also appears to have reached a deal with plaintiffs in litigation challenging its anti-aging claims.
You may also be interested in...
‘Astonishing Results’ Or ‘Outrageous’ Claims? Peter Thomas Roth Fighting Bicoastal Class Actions
Plaintiffs against the prestige, “clinical” skin-care company are targeting anti-aging claims on its Rose Stem Cell Bio-Repair line and statements about hyaluronic acid’s ultra-moisturizing capabilities, used to market its Water Drench range. PTR faces false advertising class actions in California and New York federal courts, and the former case appears to be headed for trial.
Class Action Blight: The Sour Side Of Apple Stem Cell Anti-Aging Boom
Plant stem cell actives such as Mibelle Biochemistry's PhytoCellTec Malus Domestica were marquee ingredients for skin-care brands in the flourishing US anti-aging market years back. But what once was fruitful has turned rotten with regulatory crackdowns in recent years and class actions that continue to weigh on product manufacturers.
FDA Warnings Slow, But Anti-Aging Claims Remain Class Action Targets
The online universe is abuzz with complaints about 2016, with some ready to dub the year “worst ever.” It certainly was a rough one for anti-aging skin-care marketers, and while FDA’s warning letter activity has declined of late, consumer lawsuits continue to file challenging companies’ clock-reversing promises.